Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q99986: Variant p.Arg133Cys

Serine/threonine-protein kinase VRK1
Gene: VRK1
Feedback?
Variant information Variant position: help 133 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Arginine (R) to Cysteine (C) at position 133 (R133C, p.Arg133Cys). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and basic (R) to medium size and polar (C) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In PCH1A; likely pathogenic; severely reduced kinase activity resulting in severely decreased autophosphorylation and phosphorylation of COIL, H3, H2AX, TP53, JUN and TP53BP1; reduced protein stability. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 133 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 396 The length of the canonical sequence.
Location on the sequence: help YWGSGLHDKNGKSYRFMIMD R FGSDLQKIYEANAKRFSRKT The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         YWGSGLHDKNGKSYRFMIMDRFGSDLQKIYEANAKRFSRKT

Mouse                         YWGSGLHDKNGKSYRFMIMDRFGSDLQKIYEANAKRFSRKT

Bovine                        YWGSGLHDKNGKSYRFMIIDRFGSDLQKIYEANAKRFSRKT

Zebrafish                     YWGSGFHEKNGKRYRFMVMDRFGTDLQKLFEGNGKKFSRKL

Caenorhabditis elegans        LIANGYFTYESEKMRYMIIPKYATSLEAVRETNGGTLAMKD
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 396 Serine/threonine-protein kinase VRK1
Domain 37 – 317 Protein kinase
Mutagenesis 125 – 125 S -> A. Does not abolish autophosphorylation.
Mutagenesis 150 – 150 S -> A. Does not abolish autophosphorylation.



Literature citations
Deep sequencing reveals 50 novel genes for recessive cognitive disorders.
Najmabadi H.; Hu H.; Garshasbi M.; Zemojtel T.; Abedini S.S.; Chen W.; Hosseini M.; Behjati F.; Haas S.; Jamali P.; Zecha A.; Mohseni M.; Puettmann L.; Vahid L.N.; Jensen C.; Moheb L.A.; Bienek M.; Larti F.; Mueller I.; Weissmann R.; Darvish H.; Wrogemann K.; Hadavi V.; Lipkowitz B.; Esmaeeli-Nieh S.; Wieczorek D.; Kariminejad R.; Firouzabadi S.G.; Cohen M.; Fattahi Z.; Rost I.; Mojahedi F.; Hertzberg C.; Dehghan A.; Rajab A.; Banavandi M.J.; Hoffer J.; Falah M.; Musante L.; Kalscheuer V.; Ullmann R.; Kuss A.W.; Tzschach A.; Kahrizi K.; Ropers H.H.;
Nature 478:57-63(2011)
Cited for: VARIANT PCH1A CYS-133; INVOLVEMENT IN PCH1A;
VRK1 functional insufficiency due to alterations in protein stability or kinase activity of human VRK1 pathogenic variants implicated in neuromotor syndromes.
Martin-Doncel E.; Rojas A.M.; Cantarero L.; Lazo P.A.;
Sci. Rep. 9:13381-13381(2019)
Cited for: CHARACTERIZATION OF VARIANTS HMNR10 GLN-89; ARG-119; ARG-135; VAL-195; MET-236 AND CYS-321; CHARACTERIZATION OF VARIANTS PCH1A CYS-133 AND 358-ARG--LYS-396 DEL; FUNCTION;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.